Rituximab for the treatment of systemic sclerosis-interstitial lung disease

Michael Hughes; Christopher P. Denton; Dinesh Khanna

doi:10.1093/rheumatology/keaa675

Rituximab for the treatment of systemic sclerosis-interstitial lung disease

Michael Hughes, Christopher P. Denton, Dinesh Khanna

Division of Musculoskeletal & Dermatological Sciences (L5)

Research output: Contribution to journal › Editorial › peer-review

Original language	English
Pages (from-to)	489-491
Number of pages	3
Journal	Rheumatology
Volume	60
Issue number	2
DOIs	https://doi.org/10.1093/rheumatology/keaa675
Publication status	Published - 27 Nov 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/rheumatology/keaa675

Cite this

@article{3d0347f16b4147b889dea6fb0ef59e8f,

title = "Rituximab for the treatment of systemic sclerosis-interstitial lung disease",

author = "Michael Hughes and Denton, {Christopher P.} and Dinesh Khanna",

year = "2020",

month = nov,

day = "27",

doi = "10.1093/rheumatology/keaa675",

language = "English",

volume = "60",

pages = "489--491",

journal = "Rheumatology",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "2",

}

TY - JOUR

T1 - Rituximab for the treatment of systemic sclerosis-interstitial lung disease

AU - Hughes, Michael

AU - Denton, Christopher P.

AU - Khanna, Dinesh

PY - 2020/11/27

Y1 - 2020/11/27

UR - http://dx.doi.org/10.1093/rheumatology/keaa675

U2 - 10.1093/rheumatology/keaa675

DO - 10.1093/rheumatology/keaa675

M3 - Editorial

SN - 1462-0324

VL - 60

SP - 489

EP - 491

JO - Rheumatology

JF - Rheumatology

IS - 2

ER -

Rituximab for the treatment of systemic sclerosis-interstitial lung disease

UN SDGs

Access to Document

Other files and links

Cite this